Interview with Melissa Thomas, Managing Director, Nycomed UK Ltd.
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
Address: Takeda House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Bucks, HP10 0HH
United Kingdom
Tel: +44 (0) 1628 537 900
Web: http://www.takeda.co.uk/uk/
Nycomed is a privately owned, global, market-driven pharmaceutical company with a differentiated portfolio of branded medicines in gastroenterology, respiratory, inflammatory diseases, pain, and osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. With turnover of €3.2 billion in 2009, Nycomed is among the 25 largest pharmaceutical companies in the world and the 15th largest provider of over-the-counter medicines.
In the UK, recent years have seen a dramatic shift in the prescribing landscape. Nycomed UK recognises the need to respond to these significant changes and is committed to adapting its business model to allow it to effectively manage customers’ evolving needs. To this end Nycomed UK has recently introduced a revised model that it believes will allow it to flex and adapt to not only the whole system changes laid out in the recently published White Paper, but also the geographical differences that exist within the NHS. The new structure will provide the platform for national strategies to be implemented through the optimisation of regional opportunities by tailoring the amount and type of resource utilised at a local level as appropriate.
Nycomed markets hospital products throughout Europe and general practitioner and over-the-counter medicines in selected European countries.
Protium> Gastroenterology> Pantoprazole
TachoSil> Tissue Management> 5.5mg fibrinogen/2.0IU thrombin/cm2
Alvesco> Respiratory> Ciclesonide
Preotact> Osteoporosisç> Parathyroid Hormone
Matrifen> Pain Management> Transdermal fentanyl patch
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
The two Big Pharma giants today announced the merger between their consumer healthcare businesses, with the joint venture (JV) set to become the global market leader in over-the-counter (OTC) products…
Ian Chamberlain looks at the changing role of the pharma sales manager and the skills needed to keep up with new tech and the next generation of millennial sales reps. With…
Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In his second piece for PharmaBoardroom, Aditya examines the dangers of nationalism and populism for the private sector. The biggest global risk I see…
With more than 25 years pharmaceutical industry experience, Ian Chamberlain provides training to help pharma salespeople talk to customers and provides sales managers with software to help pharma companies intelligently listen…
Yesterday, pharma giant AstraZeneca announced that they have halted investment in the UK due to lack of clarity on trading regulations during this time of Brexit uncertainty. “If a transition…
The UK Prime Minister has been convinced by medical professionals to fortify all flour with folic acid to reduce the number of birth defects in newborns. A large cohort of…
This week the NHS becomes the first in the world to routinely offer access to breakthrough genomic medicine. Today (1st October 2018) marks a huge stride in ‘precision medicine’ in the…
The UK country managers of some of the biggest global pharma companies explain what it takes to manage in the UK market. Erik Nordkamp, Pfizer Erik Nordkamp, the Dutch…
For French mid-cap Ipsen, the UK is one of three global hubs, with manufacturing in Wales, large-scale R&D activities near Oxford as well as UK Commercial Operations and global functions…
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
See our Cookie Privacy Policy Here
